What is it about?
In the brain, a protein called KCC2 transports chloride and potassium ions, helping neurons to maintain the right balance of chloride inside and outside the cell. This balance is important because it determines how well the brain's main "braking system" (a chemical signal called GABA) can control neuronal activity. When GABA works properly, it helps keep brain activity in check. In people with a common and severe form of epilepsy called mesial temporal lobe epilepsy (mTLE), this KCC2 protein doesn't work well. As a result, the chloride balance gets disrupted, and GABA — instead of calming things down — can actually excite neurons, potentially triggering seizures. Many patients with this form of epilepsy don't respond to currently available medications, so new treatment approaches are urgently needed. In this study, we tested two drug candidates — called prochlorperazine (PCPZ) and CLP-257 — that were thought to boost KCC2 activity. We found that both drugs did indeed make KCC2 work better by helping the protein to cluster together at the cell surface, essentially strengthening the efficacy of ion transport. Interestingly, CLP-257 also boosted GABA signals by acting directly one specific GABA receptors. Most importantly, when we tested these drugs on brain tissue surgically removed from epilepsy patients whose seizures didn't respond to standard medications, and also in a mouse model of temporal lobe epilepsy, both compounds successfully reduced abnormal abnormal electrical activity and seizures.
Featured Image
Photo by Robina Weermeijer on Unsplash
Why is it important?
In short, this study is highly significant because it addresses a major need in epilepsy treatment: the fact that millions of people suffer from drug-resistant forms of the condition, such as mesial temporal lobe epilepsy (mTLE), where standard medications simply do not work. For these patients, the only remaining option is often invasive brain surgery, which carries cognitive risks and does not always provide a permanent cure. The importance of this research can be broken down into three key areas: - we provide a critical proof-of-concept that we can restore KCC2 function using specific compounds to restore a healthy chemical balance in neurons. - unlike many studies, we tested these compounds on actual human brain tissue removed from epilepsy patients. We found that the treatment almost completely stopped abnormal electrical activity, showing that this approach has direct translational relevance to real people. - in animal models, we showed that these compounds could reduce the frequency of chronic seizures by 40% to 55%. Ultimately, our work opens the door to a completely new class of epilepsy drugs targeting the KCC2 protein.
Perspectives
This research provides a vital "proof-of-concept" showing that fixing the brain's internal chemical balance is a promising new way to treat severe epilepsy that does not respond to standard medications. By successfully testing new drug compounds on both animal models and actual human brain tissue, the study demonstrates a clear path toward developing real-world medical treatments. These findings pave the way for the design of even more precise and effective drugs targeting the KCC2 protein. This breakthrough offers hope to the millions of people who currently struggle with uncontrolled seizures by providing an alternative to invasive brain surgery.
Jean Christophe Poncer
Paris Brain Institute
Read the Original
This page is a summary of: Enhancing KCC2 function reduces interictal activity and prevents seizures in temporal lobe epilepsy, Proceedings of the National Academy of Sciences, March 2026, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2522722123.
You can read the full text:
Contributors
The following have contributed to this page
